No Data
No Data
With 42% Stake, Compass Therapeutics, Inc. (NASDAQ:CMPX) Seems to Have Captured Institutional Investors' Interest
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Announces Target Price $10
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Why Compass Therapeutics, Inc. (CMPX) Is Skyrocketing So Far in 2025
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
Analysts' Top Healthcare Picks: Compass Therapeutics (CMPX), LENSAR (LNSR)
Unlock the Full List